Automated T Cell Manufacturing From Start To Fill

Automating T cell manufacturing is becoming essential as cell therapy programs scale and diversify. This application-focused overview walks through an end-to-end, closed workflow that spans starting material processing through final formulation and fill. See how enrichment, activation, viral transduction, expansion, and dosing can be integrated into a single automated process while accommodating both fresh and frozen leukapheresis inputs. Performance data illustrate consistent expansion to clinically relevant cell numbers, high viabilities, and reproducible formulation across multiple fill volumes and concentrations. The workflow also demonstrates flexibility in cytokine supplementation and cryopreservation strategies without compromising product quality.

For teams focused on reducing manual handling, improving reproducibility, and streamlining GMP manufacturing, this application note provides a practical look at how automation can support reliable CAR T cell production from start to finish.